Survival rates were studied among 1258 children with acute non-lymphocytic leukaemia diagnosed in 1971-88 and included in the population based National Registry of Childhood Tumours. Of the total, 147 (12%) died without receiving treatment. Among the remaining treated children, actuarial five year survival rates were 6% in 1971-4, 15% in 1975-9, 23% in 1980-3, and 40% in 1984-8. Infants aged less than 1 year had a significantly worse prognosis and there was a significant trend towards lower survival rates with increasing white cell count. No independent significant effects on survival were found with sex, French-American-British (FAB) subtype, or the presence or absence of Down's syndrome. Children entered in national trials had a higher survival rate than those who were not entered, and children treated at teaching hospitals had a higher survival rate than those who were treated elsewhere. Among the 535 (43%) children who survived at least one year from diagnosis no factor studied had a significant effect on survival, emphasising the importance of achieving first remission as a determinant of long term survival.
The outlook for children with acute nonlymphocytic leukaemia (ANLL) diagnosed during the early 1970s was bleak, with fewer than 5% surviving for five years 1984 who were treated at a teaching hospital had a higher survival rate than those treated elsewhere. 9 The purpose of this study was to investigate possible prognostic factors, including those related to patterns of medical care, for ANLL in childhood in a large population based series and to document survival rates since 1985.
Patients and methods
The population based National Registry of Childhood Tumours ascertains cases of malignant disease in children under 15 years of age from the national cancer registration systems of England, Scotland, and Wales, specialist children's tumour registries in several regions, notifications to the MRC's leukaemia trials, the UK Children's Cancer Study Group (CCSG), and death certificates.
Confirmation of diagnosis and information on congenital abnormalities, treatment, and follow up are obtained from the hospitals at which the children were treated, from their family doctors, and from clinical trial records. Children not already known to have died are flagged in the NHS central registers so that any further deaths are automatically notified to us.
Cases ascertained from death certificates alone are not included in analyses of survival. From all other sources combined, there were 1258 children domiciled in Great Britain with ANLL (including acute monocytic leukaemia, erythroleukaemia, and megakaryocytic leukaemia) diagnosed in the period 1971-88.
For children who survived to be treated the treatment centre was defined as the hospital from which chemotherapy was directed. Where a hospital closed and treatment of childhood leukaemia was transferred to another hospital, or where treatment was administered by a team of clinicians working jointly at two hospitals, the treatment centre was taken to include both hospitals.
Follow up was complete to the end of 1992 for all but four of the survivors. Survival rates were analysed by standard methods to examine the effects of age, sex, morphological subgroups defined by the French-AmericanBritish (FAB) classification,10 white cell count, inclusion in trials, and type of treatment centre. Calendar periods of diagnosis were defined as 1971-4, 1975-9, 1980-3, and 1984-8, to coincide approximately with the periods of accrual to successive national trials. Survival rates were also analysed for all children who survived at least three months to investigate whether significant prognostic factors for the entire series were still important when patients who had probably not entered remission were excluded; exclusion of children who died within three months should also eliminate possible bias if patients who were perceived to have a poor prognosis were selectively not entered in trials or referred to teaching hospitals. Survival rates for one year survivors were analysed to study factors influencing survival when patients who had relapsed relatively early were also excluded. Table 1 shows the actuarial five year survival rates for successive calendar periods of diagnosis. Of the 1258 children in the study, 147 (12%) died without receiving treatment for their leukaemia. There was little sign of any change in the proportion of untreated children with the period of diagnosis. The proportion of untreated children was higher when ANLL occurred with Down's syndrome. Among the 72 children with Down's syndrome in the study, 44 (61%) were untreated; these included 13 (87%) of the 15 Down's syndrome children who also had cardiac abnormalities and 13 (93%) of the 14 who were aged less than 1 year at diagnosis. The proportion of non-Down's syndrome children who were untreated also decreased with increasing age at diagnosis from 32% (33/102) at age 0 to 10% (12/122) at age 1 year and 6% (58/962) at age 2-14 years. There were only three non-Down's syndrome children recorded as having cardiac abnormalities and all three received treatment for their leukaemia.
Results
The other analyses are based on the 11 11 children who received treatment for ANLL. There was a highly significant trend in survival Among treated patients there was no significant difference in survival rates between the sexes. Children with Down's syndrome who received treatment for their leukaemia had a similar survival rate to non-Down's syndrome children. There was a significant variation in survival with age at diagnosis (fig 2: X2=12 7 on 5 df, p<005); this was largely due to a much lower rate among infants aged less than 1 year (X2=9-98 on 1 df, p<001), particularly during the first year after diagnosis, though their long term survival was similar to that of older children.
There was a highly significant trend towards lower survival rates for children with a higher white cell count (fig 3: X2= 17 (myelomonocytic) leukaemia were more likely to have a higher count. A combined analysis of age, white cell count and FAB subtype was therefore carried out for children diagnosed in 1980-8, the effects of each factor being analysed while allowing for the other two. The Years since diagnosis Figure 3 Actuarial survival curves for childrenfirst treated during the peiod classified by white cell count (WCC).
trend in survival with white cell count was still statistically significant (X2= 10 7 on 1 df, p<00 1), but the effects of age and FAB subtype were not.
The proportion of children treated at teaching hospitals increased throughout the study period, with the largest increase being between 1971-4 and 1975-9 (table 3). There was little variation with age in the proportion of children treated at teaching hospitals. Table 4 
of children aged 2-12 years when first treated were entered in trials, compared with 34% of those aged under 2 years and 29% of those aged 13-14 years. In all periods children treated at teaching hospitals were more likely to be entered into trials than those who were treated elsewhere.
Children entered in trials had a higher survival rate than non-trial children (fig 4: X2=8 84 on 1 df, p<0 01, allowing for age). A total of 897 (81%) children survived at least three months. In this group the trend towards higher survival in more recent periods of diagnosis was still highly significant (X2=90¢5 on 1 df, p<00001). Survival rates were similar for boys and girls, and for Down's syndrome and non-Down's syndrome children. The lower survival rate for those aged less than 1 year at diagnosis just failed to attain statistical significance (X2=3-81 on 1 df) but there were only 49 infants among the three month survivors. The effect of white cell count was still highly significant (X2= 10 9 on 1 df for trend, p<0 01). The FAB subtype had no effect on survival. Children entered in trials had a higher survival rate than those who were not, though not significantly so (X2=3 17 on 1 df allowing for age). There was also no significant effect of type of treatment centre (X2=1*28 on 1 df allowing for age).
Among the 535 (48%) children who survived at least one year, the trend in survival rates with period of diagnosis was still highly significant x2=72X8 on 1 df, p<0 0001). There was no Years since diagnosis Figure 4 Actuarial survival curves for childrenfirst treated during the period 1975-88 classified by whether they were entered into national trials. Years since diagnosis Figure 5 In the two series there was no difference in survival between the sexes. Infants aged less than 1 year had a significantly worse survival rate which was entirely due to higher mortality during the first year after diagnosis in the two studies. There was a highly significant trend of lower survival rates with increasing white cell count; in our study this was also confined to the first year after diagnosis.
The analysis of survival rates by FAB classification was limited by several factors. Firstly, the subtype often could not be reliably deduced from the registry records, particularly for children diagnosed before 1980; before that date the distinction between type Ml and M2 leukaemia could rarely be made and M7 megakaryocytic leukaemia was not reliably identified. Secondly, the classifications are those reported by individual haematologists responsible for diagnosis. Interobserver variation in assigning subtypes is well documented, especially in distinguishing between M1 and M2 and in diagnosing M4, though agreement on classifying M5 (monocytic) leukaemia is greater.'3 This subtype has been reported as occurring in a relatively high proportion of infants and young children'4 15; in the present study, 33% of children aged 0-2 years and first treated in the period 1980-8 were recorded as being of type M5, compared with 11% of older children. M5 morphology has sometimes been reported as being associated with a lower survival rate'5 16 but this was not so in our study. Patients with M3 (promyelocytic) leukaemia have been reported to have a good long term prognosis if they achieve remission. Among children in the present study who survived at least three months, however, there was little difference in subsequent survival rates between those with M3 leukaemia and those with other morphological subtypes. A higher survival rate for M2 leukaemia has been reported,'7 but again we found little evidence for this. Other investigators have also found no significant effect of morphology, including the CCSG study which was based on large numbers of children.12 18 Children with Down's syndrome who were treated for ANLL had a similar survival rate to non-Down's syndrome children. This result is in agreement with a previous report,'9 but many patients in the present series were also in that earlier study. It appears that, unlike in acute lymphoblastic leukaemia, the presence of Down's syndrome is not an unfavourable prognostic factor for childhood ANLL. A higher proportion of Down's syndrome children than non -Down's syndrome children did not receive any treatment for their leukaemia, however, even in the most recent calendar period. 
